Related Experiment Video
Updated: Oct 9, 2026
Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
Published on: November 10, 2013
Antiproliferative activity and interactions with cell-cycle related proteins of the organotin compound
F Barbieri1, F Sparatore, M Cagnoli
1Laboratory of Pharmacology and Neuroscience, Istituto Nazionale per la Ricerca sul Cancro, Largo R. Benzi 10, 16132, Genoa, Italy.
Abstract:
Organotin compounds, particularly tri-organotin, have demonstrated cytotoxic properties against a number of tumor cell lines. On this basis, triethyltin(IV)lupinylsulfide hydrochloride (IST-FS 29), a quinolizidine derivative, was synthesized and developed as a potential antitumor agent. This tin-derived compound exhibited potent antiproliferative effects on three different human cancer cell lines: teratocarcinoma of the ovary (PA-1), colon carcinoma (HCT-8) and glioblastoma (A-172). Cytotoxic activity was assessed by MTT and cell count assays during time course experiments with cell recovery after compound withdrawal. Significant cell growth inhibition (up to 95% in HCT-8 after 72 h of exposure), which also persisted after drug-free medium change, was reported in all the cell lines by both assays. In addition, the cytocidal effects exerted by IST-FS 29 appeared more consistent with necrosis or delayed cell death, rather than apoptosis, as shown by morphologic observations under light microscope, DNA fragmentation analysis and flow cytometry. In the attempt to elucidate whether this compound might affect genes playing a role in G1/S phase transition, the expressions of p53, p21(WAF1), cyclin D1 and Rb, mainly involved in response to DNA-damaging stress, were analyzed by Western blot. Heterogeneous patterns of expression during exposure to IST-FS 29 were evidenced in the different cell lines suggesting that these cell-cycle-related genes are not likely the primary targets of this compound. Thus, the present data seem more indicative of a direct effect of IST-FS-29 on macromolecular synthesis and cellular homeostasis, as previously hypothesized for other organotin complexes.
Insights
Triethyltin(IV)lupinylsulfide hydrochloride (IST-FS 29) shows potent antitumor activity, inhibiting cancer cell growth and potentially impacting macromolecular synthesis and cellular homeostasis.
Area of Science:
- Medicinal Chemistry
- Oncology
- Toxicology
Background:
- Organotin compounds, especially tri-organotin, exhibit known cytotoxic effects against various tumor cell lines.
- This study focuses on a novel quinolizidine derivative, triethyltin(IV)lupinylsulfide hydrochloride (IST-FS 29), as a potential anticancer agent.
Purpose of the Study:
- To synthesize and evaluate the antitumor potential of IST-FS 29 against human cancer cell lines.
- To investigate the mechanism of action, including cell death pathways and effects on cell-cycle regulatory genes.
Main Methods:
- Synthesis of IST-FS 29, a novel organotin compound.
- In vitro antiproliferative and cytotoxic assays (MTT, cell count) on ovarian teratocarcinoma (PA-1), colon carcinoma (HCT-8), and glioblastoma (A-172) cell lines.
- Morphological analysis, DNA fragmentation assay, and flow cytometry to determine cell death mechanism.
- Western blot analysis to assess the expression of cell-cycle-related genes (p53, p21(WAF1), cyclin D1, Rb).
Main Results:
- IST-FS 29 demonstrated significant antiproliferative effects across all tested cancer cell lines, with up to 95% inhibition in HCT-8 cells after 72 hours.
- Inhibition persisted even after drug removal, suggesting a lasting effect.
- Cell death appeared to be necrosis or delayed cell death rather than apoptosis.
- Expression patterns of p53, p21(WAF1), cyclin D1, and Rb were heterogeneous and not consistently altered, indicating they are unlikely primary targets.
Conclusions:
- IST-FS 29 exhibits potent anticancer activity against ovarian, colon, and glioblastoma cell lines.
- The compound's mechanism may involve direct disruption of macromolecular synthesis and cellular homeostasis, rather than targeting key cell-cycle regulatory genes.
- Further research into organotin compounds like IST-FS 29 is warranted for developing novel antitumor therapies.
